Semaglutide to be evaluated for significant fibrosis in obese and T2DM patients with NAFLD
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
Abstract
Open-label clinical trial to evaluate oral Semaglutide for significant fibrosis due to NAFLD in obese or T2DM patients.